文献速递核素与放射性配体治疗放射性药物与辐射防护

神经内分泌肿瘤患者接受放射性配体治疗时基线肾小球滤过率对并发症与结局的影响

Complications and outcomes of radioligand therapy in patients with neuroendocrine neoplasms depending on the baseline glomerular filtration rate.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-06-24

研究纳入127例进展期神经内分泌肿瘤(NENs)患者,接受一个周期放射性配体治疗(RLT),按基线肾功能分为低滤过率与正常滤过率两组,评估肾、骨髓、血糖及嗜铬粒蛋白A在治疗前、第IV程及随访中的变化。结果显示RLT期间肾小球滤过率(GFR)无显著下降,但长期随访中观察到超过6%的GFR下降;血液形态学参数在治疗期间显著下降并持续至长期观察;基线GFR较低组GFR值有所改善。60个月无进展生存(PFS)与总生存(OS)概率分别为41.5%与74%。

要点

  • RLT期间GFR无显著下降,但长期随访中观察到超过6%的GFR下降。
  • 血液形态学参数在治疗期间显著下降,长期观察中仍保持下降。
  • 基线GFR较低患者GFR值有所改善,初始低GFR似乎不限制RLT的可能性。

核心结论

  • RLT导致所有血液形态学参数出现统计学显著但非临床显著的下降。
  • 长期观察中观察到GFR下降和血糖浓度升高。
  • 初始低GFR似乎不限制RLT的可能性,该组患者甚至可能出现GFR升高。

研究设计与样本

  • 研究纳入127例进展期神经内分泌肿瘤(NENs)患者,接受一个周期放射性配体治疗(RLT)。
  • 在I程前、IV程及随访中评估肾功能、骨髓、血糖和嗜铬粒蛋白A;44例代表性子组参加长期随访。

主要发现

  • RLT期间未导致GFR显著下降,但长期随访中观察到超过6%的GFR下降。
  • 血液形态学参数在治疗期间显著下降,并在长期观察中保持下降。
  • 血糖浓度在治疗期间无变化,但长期观察中 noted 12 mg/dL的升高。
  • 基线GFR较低患者的GFR值有所改善。
  • 治疗后60个月计算的无进展生存(PFS)概率为41.5%,总生存(OS)概率为74%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Neuroendocrine neoplasms (NENs) represent a rare group of neoplasms originating from neuroendocrine cells in almost any part of the body. One of subsequent line of treatment is radioligand therapy (RLT) with use of beta-emitting isotopes. The most common adverse events are deterioration of kidney and bone marrow function. The aim of the study was to assess the differences in complications and outcomes of RLT between patients with initially low and normal renal function. METHODS: Study group included 127 patients with progressive NENs who underwent one cycle of RLT. Renal, bone marrow, glucose, and chromogranin A were assessed before Course I, Course IV and in follow-up. A representative subgroup of 44 patients reported for long-term visit. RESULTS: RLT did not cause significant decrease of GFR during the treatment, however over 6% GFR decrease was observed in long-term follow-up. Blood morphology parameters significantly decreased during the treatment, and remained decreased in long-term observation. Glucose concentration did not change during the treatment, though an increase of 12 mg/dL in long-term observation was noted. Patients with initially lower GFR had improvement in GFR values. Calculated PFS and OS probability at 60 months after treatment were 41.5% and 74% respectively. CONCLUSIONS: RLT cause a statistically but not clinically significant decrease of all blood morphology parameters. In long-term observation after RLT a decrease of GFR and increase in glucose concentration are observed. Initially low GFR seems not to limit the possibility of RLT, and even GFR increase in this group of patients is possible.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Durma AD, Saracyn M, Jóźwik-Plebanek K, et al. Complications and outcomes of radioligand therapy in patients with neuroendocrine neoplasms depending on the baseline glomerular filtration rate. Eur J Nucl Med Mol Imaging. 2025. PMID: 40553118. doi:10.1007/s00259-025-07418-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。